Absci Corp. (ABSI)
Health Services • Health Care
July 14, 2026 Absci Corp. Set to Release Q2 2026 Financial Results on August 11 Absci Corporation is set to release its Q2 2026 financial results on August 11, followed by a conference call discussing its innovative drug pipeline and financial health. The company continues to lead in biopharmaceuticals with its unique AI-driven drug discovery approach.
June 24, 2026 Absci Corp. Prices $100 Million Underwritten Offering: A Step Towards Advancing Biopharmaceutical Innovation Absci Corporation has priced a $100 million underwritten offering to fund its innovative ABS-201 program targeting androgenetic alopecia and endometriosis. The offering has attracted significant investor interest, underscoring confidence in Absci's AI-driven drug discovery approach.
June 24, 2026 Absci Corp. Reports Promising Interim Phase 1 Results for ABS-201 in HEADLINE™ Trial Absci Corporation reported encouraging interim findings from its Phase 1 HEADLINE™ trial for ABS-201, an investigational antibody for androgenetic alopecia. The results show a favorable safety profile and potential for infrequent dosing, paving the way for further clinical development.
May 20, 2026 Absci Corporation Set to Showcase Innovations in Upcoming Investor Conferences Absci Corporation announces its participation in the Jefferies and Goldman Sachs healthcare conferences in June 2026, where it will showcase its advancements in AI-driven drug discovery. The company aims to engage with investors on its promising pipeline, including ABS-201 for hair regrowth and endometriosis.
May 07, 2026 Absci Corp. Reports Financial Results and Strategic Updates for Q1 2026 Absci Corporation reports its Q1 2026 financial results, showcasing advancements in clinical trials for ABS-201 targeting androgenetic alopecia and endometriosis. The company remains optimistic about a data-rich year ahead, with significant developments in its drug pipeline and a focus on partnerships.
May 05, 2026 Absci Corp. Grants Stock Options to New Employee, Strengthening Talent Acquisition Strategy Absci Corporation has awarded stock options to a new employee as part of its strategy to attract and retain talent in the biotech industry. The grant includes 276,200 shares with a structured vesting schedule and reflects the company's commitment to innovation and employee alignment with shareholder interests.
April 23, 2026 Absci Corporation Set to Reveal Q1 2026 Results and Business Updates Absci Corporation will announce its Q1 2026 results on May 7, 2026, followed by a live webcast. The event will provide insights into the company's financial performance and innovative projects, including the promising ABS-201™ treatment.
April 08, 2026 Absci Corp. to Showcase Innovations at 25th Annual Needham Virtual Healthcare Conference Absci Corporation will participate in the 25th Annual Needham Virtual Healthcare Conference on April 16, 2026, discussing its innovative drug discovery technologies. The company's Integrated Drug Creation™ platform and promising pipeline, including ABS-201™ for hair regrowth and endometriosis, highlight its commitment to addressing significant medical needs.
March 24, 2026 Absci Corporation Reports Q4 and Full Year 2025 Results, Highlights Advancements in AI-Driven Therapeutics Absci Corporation announced its Q4 2025 financial results, showcasing progress in its therapeutic pipeline, particularly with ABS-201 for AGA and endometriosis. Key developments include the appointment of a new Chief Medical Officer and promising safety data from ongoing clinical trials, setting the stage for a transformative 2026.
March 24, 2026 Absci Corp. Launches Advisory Board for ABS-201 Endometriosis Program Absci Corporation has launched an advisory board for its ABS-201 endometriosis program, aimed at developing innovative therapies for the 190 million affected globally. The board consists of leading experts from renowned institutions, focusing on a novel anti-prolactin receptor antibody that promises to improve treatment outcomes without hindering fertility.
March 24, 2026 Absci Corp. Reports 2025 Annual Results: A Year of Strategic Advances Amidst Financial Challenges Absci Corp. reported significant financial losses in 2025 but achieved key milestones in drug development, including advancements in clinical trials and strategic partnerships. The company is positioned for future growth through innovative AI-driven therapies.
March 06, 2026 Absci Corp. Announces Key Inducement Grant Amid Strategic Growth Absci Corporation has appointed Dr. Ransi Somaratne as its Chief Medical Officer, granting him 650,000 stock options to enhance its competitive edge. The company continues to innovate through its AI-driven drug discovery platform, paving the way for promising therapeutics like ABS-201 for hair loss and endometriosis.
March 03, 2026 Absci Corp. Strengthens Clinical Leadership with New CMO Appointment Absci Corporation has appointed Dr. Ransi Somaratne as its new Chief Medical Officer to enhance its clinical development strategy. With a strong background from Vertex Pharmaceuticals and significant contributions to groundbreaking therapies, his leadership is expected to accelerate Absci's innovative AI-designed therapeutics pipeline.
February 24, 2026 Absci Corporation to Deliver 2025 Financial Results and Business Updates Absci Corporation will report its 2025 financial results on March 24, 2026, followed by a conference call to discuss business updates. The company is known for its AI-driven drug discovery innovations and notable projects like ABS-201™.
February 17, 2026 Absci Corporation Announces Participation in Key Investor Conferences Absci Corporation is set to participate in major investor conferences, showcasing its advancements in drug discovery and AI technologies. Highlighting its innovative platform and promising therapeutics, Absci aims to enhance engagement with the investment community.
December 16, 2025 Absci Corp. Set to Make Waves at the 44th Annual J.P. Morgan Healthcare Conference Absci Corporation is set to present at the 44th Annual J.P. Morgan Healthcare Conference, focusing on its generative AI innovations and the promising ABS-201™ therapeutic. The company aims to redefine drug discovery and address significant health issues.
December 11, 2025 Absci Corporation Reports Promising Data for ABS-201 in Hair Growth Treatment Absci Corporation's ABS-201 shows significant promise in promoting hair growth and reversing follicle miniaturization in androgenetic alopecia, as demonstrated in preclinical studies. The targeted treatment inhibits prolactin receptors, enhancing hair follicle regeneration and addressing a root cause of hair loss.
December 10, 2025 Absci Corp. Partners with Landon Donovan to Advocate for Hair Loss Research Absci Corp. collaborates with soccer legend Landon Donovan to raise awareness about hair loss and support the development of ABS-201, a promising treatment for AGA. Donovan shares his personal experiences to highlight the emotional impact of hair loss, emphasizing the need for innovative solutions.
December 04, 2025 Absci Corporation Doses First Participants in Groundbreaking Phase 1/2a Trial for ABS-201 Absci Corporation has commenced its Phase 1/2a HEADLINE trial for ABS-201, targeting hair loss and endometriosis. This trial aims to establish the safety and efficacy of the AI-engineered therapeutic, marking a significant step in regenerative medicine.
November 12, 2025 Absci Corporation's Q3 2025 Financial Update: A Strategic Shift Towards ABS-201 Absci Corporation's Q3 2025 financial update reveals a strategic shift to prioritize ABS-201, targeting androgenetic alopecia and endometriosis. The company reported promising Phase 1 results for ABS-101 and plans to accelerate its trials while maintaining a robust financial position to support ongoing development.
November 12, 2025 Absci Corp. Reports Q3 2025 Financial Results: Navigating Challenges and Opportunities Absci Corp. reports a net loss of $28.7 million for Q3 2025, with revenues declining to $0.4 million. Despite financial challenges, the company focuses on its innovative antibody pipeline and strategic partnerships for future growth.
October 29, 2025 Absci Corp. Set to Reveal Q3 2025 Financial Results on November 12 Absci Corp. (Nasdaq: ABSI) is set to announce its Q3 2025 financial results on November 12, with a conference call scheduled for later that day. The company continues to innovate in drug discovery through its AI-driven platform, with promising projects targeting inflammatory bowel disease and androgenetic alopecia.
October 27, 2025 Absci Corporation Sets Stage for Future Growth with Upcoming Investor Conferences Absci Corporation is set to participate in several key investor conferences in November, showcasing its innovative AI-driven drug discovery strategies. With a promising pipeline, including treatments for inflammatory bowel disease and hair regrowth, Absci aims to strengthen investor relationships and highlight its commitment to advancing therapeutics.
October 15, 2025 Absci Corp. Accelerates ABS-201 Program: Key Opinion Leader Seminar Set for December Absci Corp. is set to accelerate its ABS-201 program for treating androgenetic alopecia, with a seminar featuring dermatology leaders on December 11, 2025. The company anticipates initiating Phase 1/2a trials in early December, aiming to provide a superior solution for hair loss compared to existing treatments.
August 12, 2025 Absci Corp. Reports Q2 2025 Financial Results: Navigating Through Challenges in Biopharmaceutical Development Absci Corp. reports its Q2 2025 financial results, showing a revenue decline amid increased R&D expenses and significant net losses. The company emphasizes its innovative drug development platform and strategic collaborations as key to navigating future challenges.
May 13, 2025 Absci Corp. Reports Q1 2025 Financial Results: A Step Forward in Biopharmaceutical Innovation Absci Corp. reports Q1 2025 financial results with increased revenue of $1.2 million, despite a net loss of $26.3 million. The company is advancing its drug creation platform and forming strategic partnerships, notably with AMD, to enhance its capabilities.
March 26, 2025 Absci Corporation Set to Showcase Innovations at Upcoming Investor Conferences Absci Corporation is set to present its innovative Integrated Drug Creation™ platform at two major investor conferences in April. These events will provide a platform for showcasing their advancements in AI-driven drug development and engaging with investors and industry stakeholders.
March 18, 2025 Absci Corp. Reports 2024 Annual Results: Financial Performance and Future Prospects Absci Corp. reports a challenging 2024 with a net loss of $103.1 million, despite raising $80.8 million through stock offerings. The company continues to invest in R&D with promising candidates for drug development and strategic collaborations aimed at enhancing its product pipeline.
March 18, 2025 Absci Corporation Reports Significant Business Updates and Financial Results for 2024 Absci Corporation reported promising advancements in its drug creation platform for 2024, including the ABS-201 program for androgenic alopecia. Despite a net loss, the company is positioned for growth with strategic collaborations and upcoming clinical trials in 2025.
March 16, 2025 SWOT Analysis of Absci Corp. in 2025 This SWOT analysis reviews Absci Corp.'s strategic position in the biotechnology sector as it heads towards 2025. It outlines key strengths like advanced technology and partnerships, while addressing significant weaknesses such as financial losses. The analysis also explores growth opportunities and potential threats in a competitive landscape.
March 04, 2025 Absci Corp. Prepares for Financial Report and Business Update Absci Corporation is set to release its 2024 financial results on March 18, 2025, followed by a conference call to discuss key developments. Investors are eager for insights into the company's innovative drug creation technologies and future strategies.
March 04, 2025 Absci Corp. Announces Inducement Grant Under Nasdaq Listing Rule Absci Corporation has granted a significant inducement stock option to a new non-executive employee, aimed at enhancing its talent pool. The grant includes 162,800 shares with a 10-year term and a four-year vesting period, highlighting Absci's commitment to innovation in drug development.
March 04, 2025 Absci Corporation to Feature at KeyBanc Capital Markets Healthcare Forum Absci Corporation will participate in the KeyBanc Capital Markets Healthcare Forum on March 19th, showcasing its AI-driven drug development innovations. The event will highlight Absci’s Integrated Drug Creation™ platform, which accelerates the transition from AI-designed to validated drug candidates.
February 18, 2025 Absci Corp. Gears Up for TD Cowen 45th Annual Health Care Conference Absci Corporation will showcase its cutting-edge generative AI drug development at the TD Cowen 45th Annual Health Care Conference on March 3, 2025. The company aims to engage investors while discussing its Integrated Drug Creation platform and global expansion efforts.
November 12, 2024 Absci Corp. Reports 2024 Q3 Financial Results: Progress Amidst Losses Absci Corp. reported Q3 2024 revenues of $1.7 million, marking significant growth despite a net loss of $27.4 million. The company emphasizes R&D and strategic partnerships to navigate financial challenges and enhance drug discovery capabilities.
August 14, 2024 Absci Corp. Reports Q2 2024 Financial Results: Navigating Challenges in Drug Discovery Absci Corp. reported Q2 2024 financial results with a revenue drop to $1.3 million, though net losses improved significantly. The company is focusing on advancing its drug development pipeline and maintaining liquidity to support future growth.
May 14, 2024 Absci Corp. Reports Mixed Financial Results for Q1 2024 Absci Corp's Q1 2024 financial results reveal a revenue decline but improved net losses and a strong liquidity position of $161.5 million. Recent capital raising activities support ongoing R&D initiatives amid a challenging landscape.
March 21, 2024 Absci Corp. Reports 2023 Annual Financial Results: A Year of Strategic Adjustments Absci Corp. reports a 26% revenue increase to $5.7 million, despite a widening net loss of $110.6 million. The company emphasizes cost management and strategic partnerships for future growth in biopharmaceutical innovation.